Infectious Diseases News and Research

RSS

Meridian Bioscience revises fiscal 2010 guidance, expects net sales between $145M and $153M

Meridian Bioscience, Inc., Cincinnati, Ohio today announced that it is revising downward its previous sales and earnings guidance for the fiscal year ending September 30, 2010. This action is being taken as a result of weaker than expected operating results for the second quarter ending March 31, 2010, based on preliminary results to date. Separately, Meridian announced that it will file a 510(k) for FDA marketing clearance next week in connection with its illumigene™ C. difficile product.

17 Mar 2010

Simple common sense behaviors can help limit the spread of H1N1 in household: Study

Simple, common sense behaviors, including having a discussion at home about how to prevent influenza, can help limit the spread of H1N1 in a household, according to a study of the initial outbreak in New York City in 2009.

17 Mar 2010

Studies examine ways to increase healthcare personnel vaccination rates through social networking

Healthcare personnel influenza immunization rates have remained low, despite recommendations from the Centers for Disease Control and Prevention (CDC) and other leading healthcare organizations that all healthcare personnel receive annual flu vaccines.

17 Mar 2010

Black children less likely to develop shingles after receiving chickenpox vaccine

Black children are less likely than white or Asian children to develop shingles (herpes zoster) after receiving the varicella vaccine to prevent chickenpox, reports a study in the March issue of The Pediatric Infectious Disease Journal.

17 Mar 2010

IDSA calls for global commitment to develop 10 new antibiotics by 2020

As the deaths and suffering caused by antibiotic-resistant bacterial infections continue to rise around the world, the Infectious Diseases Society of America (IDSA) is urging a global commitment to develop 10 new antibiotics by 2020, known as the 10 x '20 initiative, to address this public health crisis and safeguard patients' health.

17 Mar 2010

International Liver Congress 2010: Achillion Pharmaceuticals' protease inhibitor abstract accepted for presentation

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced that its abstract titled "Virological Response, Safety, and Pharmacokinetic Profile Following Single- and Multiple-Dose Administration of ACH-0141625 Protease Inhibitor to Healthy Volunteers and HCV Genotype-1 Patients" has been accepted as a late breaking poster presentation at the International Liver Congress™ 2010 being held April 14-18 in Vienna, Austria.

17 Mar 2010

Novavax reports net loss of $14M for fourth-quarter of 2009

StockPreacher.com announces an investment report featuring Novavax Inc. (Nasdaq:NVAX). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

16 Mar 2010

Research suggests anti-cancer drugs can help treat infectious diseases

Drugs increasingly used to treat cancer could have a major impact on a wide range of infectious diseases, according to new research.

16 Mar 2010

National childhood varicella vaccination program reduces chickenpox hospitalization rates

Since the varicella vaccine was introduced in the mid-1990s, the number of patients receiving medical care for chickenpox in the United States has decreased sharply—particularly among children, according to a study in the March issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

16 Mar 2010

Kettering Health Network licenses DIATHERIX Laboratories' TEM-PCR testing process

Kettering Health Network is the nation's first health system to use a new testing process developed by DIATHERIX Laboratories, which dramatically reduces the time it takes to detect H1N1, methicillin resistant staphylococcus (MRSA), Clostridium difficile (C-diff) and other infectious diseases. Kettering Medical Center will be the first hospital in the network to use the testing system and DIATHERIX will maintain an onsite lab at the facility.

16 Mar 2010

MicuRx Pharmaceuticals files IND for MRX-I antibiotic drug candidate with Chinese SFDA

MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that it has filed an Investigational New Drug (IND) application with the State Food and Drug Administration (SFDA) in China for MRX-I, its first development-stage antibiotic drug candidate. MRX-I, an orally-administered oxazolidinone, targets multi-drug resistant Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

15 Mar 2010

Enzo Biochem to market MultiGEN’s multiplex DNA sequencing based diagnostic tests in state of New York

Enzo Biochem, Inc. today announced that it has entered into an agreement with MultiGEN Diagnostics Inc., of San Diego, California, for exclusive rights to market MultiGEN’s unique diagnostic tests based on multiplex DNA sequencing, in the state of New York. In addition, Enzo has been granted marketing rights for other non-exclusive territories in United States.

15 Mar 2010

Study finds new way to reduce risk of life-threatening bloodstream infections in newborns

Hospitals may reduce the risk of life-threatening bloodstream infections in newborns with peripherally inserted central venous catheters by replacing the device every 30 days or so, according to a new Johns Hopkins Children's Center study.

15 Mar 2010

Immunizing children against seasonal influenza can protect unvaccinated community against influenza

Results of a clinical trial conducted in a largely self-contained religious community during the 2008-09 influenza season show that immunizing children against seasonal influenza can significantly protect unvaccinated community members against influenza as well. The study was conducted to determine if immunized children could act as a barrier to limit the spread of influenza to the wider, unvaccinated community, a concept known as herd immunity.

15 Mar 2010

Discovery may yield new strategies for blocking malaria transmission

Scientists studying the Anopheles gambiae mosquito - the main vector of malaria - have found that when the mosquito takes a blood meal, that act triggers two enzymes to form a network of crisscrossing proteins around the ingested blood.

15 Mar 2010

ampliPHOX detection technology of InDevR in beta site-testing in anticipation of upcoming product launch

InDevR, developer of advanced life science products, announced that its ampliPHOX Colorimetric Detection Technology is being beta site-tested in anticipation of an upcoming product launch. The original intellectual property was licensed from the University of Colorado at Boulder.

12 Mar 2010

Achillion Pharmaceuticals reports net loss of $6.7M for three months ended December 31, 2009

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three and twelve months ended December 31, 2009.

12 Mar 2010

PolyMedix presents data from PMX-30063 defensin-mimetic antibiotic compound Phase 1B study at 8th TSIS

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has presented for the first time to the medical community data from its Phase 1B clinical study with its defensin-mimetic antibiotic compound, PMX-30063.

12 Mar 2010

bioMerieux introduces FDA cleared chromID VRE for detecting Enterococcus faecium and Enterococcus faecalis

bioMerieux – a world leader in the field of in vitro diagnostics – today announced the launch of the first Food and Drug Administration (FDA) cleared chromID™ VRE, a simple and cost-effective solution in the struggle against vancomycin-resistant enterococci (VRE). chromID VRE is the first to receive an FDA 510(k) clearance for the qualitative detection of Enterococcus faecium and Enterococcus faecalis showing acquired resistance to vancomycin in stool specimens.

12 Mar 2010

Baxter International, DVC present Phase III clinical efficacy data for PREFLUCEL

Baxter International Inc., in conjunction with DynPort Vaccine Company LLC, a CSC Company, today presented Phase III study data measuring the clinical efficacy for PREFLUCEL, a trivalent seasonal influenza candidate vaccine. PREFLUCEL is made using Baxter’s Vero cell culture platform and does not contain an adjuvant or preservatives. The data were presented at the International Congress on Infectious Disease (ICID) in Miami, Florida.

From Baxter International Inc. 12 Mar 2010

Infectious Diseases News and Research

Meridian Bioscience revises fiscal 2010 guidance, expects net sales between $145M and $153M

Simple common sense behaviors can help limit the spread of H1N1 in household: Study

Studies examine ways to increase healthcare personnel vaccination rates through social networking

Black children less likely to develop shingles after receiving chickenpox vaccine

IDSA calls for global commitment to develop 10 new antibiotics by 2020

International Liver Congress 2010: Achillion Pharmaceuticals' protease inhibitor abstract accepted for presentation

Novavax reports net loss of $14M for fourth-quarter of 2009

Research suggests anti-cancer drugs can help treat infectious diseases

National childhood varicella vaccination program reduces chickenpox hospitalization rates

Kettering Health Network licenses DIATHERIX Laboratories' TEM-PCR testing process

MicuRx Pharmaceuticals files IND for MRX-I antibiotic drug candidate with Chinese SFDA

Enzo Biochem to market MultiGEN’s multiplex DNA sequencing based diagnostic tests in state of New York

Study finds new way to reduce risk of life-threatening bloodstream infections in newborns

Immunizing children against seasonal influenza can protect unvaccinated community against influenza

Discovery may yield new strategies for blocking malaria transmission

ampliPHOX detection technology of InDevR in beta site-testing in anticipation of upcoming product launch

Achillion Pharmaceuticals reports net loss of $6.7M for three months ended December 31, 2009

PolyMedix presents data from PMX-30063 defensin-mimetic antibiotic compound Phase 1B study at 8th TSIS

bioMerieux introduces FDA cleared chromID VRE for detecting Enterococcus faecium and Enterococcus faecalis

Baxter International, DVC present Phase III clinical efficacy data for PREFLUCEL

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News